Onderneming R&G PharmaStudies Co., Ltd.
Aandelen
301333
CNE100005K44
Gezondheidszorgvoorzieningen & -diensten
slotkoers
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
48,91 CNY | -0,99% | +1,10% | -24,15% |
Vakgebied
Aantal werknemers: 2 042
Verkoop per activiteit
CNY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Clinical Trial Operation
49,1
%
| 300 | 47,0 % | 354 | 49,1 % | +18,32% |
Clinical Trial Site Management
25,8
%
| 154 | 24,2 % | 186 | 25,8 % | +20,58% |
Data Management and Statistical Analysis
11,0
%
| 73 | 11,4 % | 80 | 11,0 % | +9,87% |
Biological Sample Testing
5,1
%
| 45 | 7,0 % | 36 | 5,1 % | -18,61% |
Clinical Pharmacology
5,0
%
| 32 | 5,0 % | 36 | 5,0 % | +12,39% |
Clinical Trial Consulting
4,0
%
| 34 | 5,4 % | 29 | 4,0 % | -16,12% |
Verkoop per regio
CNY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
China
93,5
%
| 605 | 94,9 % | 674 | 93,5 % | +11,47% |
Overseas
6,5
%
| 32 | 5,1 % | 47 | 6,5 % | +44,57% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jie Wu
CEO | Chief Executive Officer | 63 | 22-08-08 |
Shu Qi Li
FOU | Founder | 59 | 22-08-08 |
Qian Zhao
DFI | Director of Finance/CFO | 40 | 01-02-14 |
Hong Guan
CHM | Chairman | 47 | 01-04-10 |
Yan Zheng
CTO | Chief Tech/Sci/R&D Officer | 40 | 01-07-09 |
Wei Guo Zhang
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-04-14 |
Wei Wang
BRD | Director/Board Member | 46 | 01-08-08 |
Le Yan Teng
BRD | Director/Board Member | 52 | 01-10-09 |
Gang Chen
PRN | Corporate Officer/Principal | 68 | 01-07-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Le Yan Teng
BRD | Director/Board Member | 52 | 01-10-09 |
Shu Qi Li
FOU | Founder | 59 | 22-08-08 |
Hong Bei Zheng
BRD | Director/Board Member | 58 | 01-01-15 |
Jie Wu
CEO | Chief Executive Officer | 63 | 22-08-08 |
Wei Wang
BRD | Director/Board Member | 46 | 01-08-08 |
Qian Chen
BRD | Director/Board Member | 63 | 01-01-16 |
Hong Li
BRD | Director/Board Member | 55 | 01-09-15 |
Lu Yang
BRD | Director/Board Member | 42 | 01-09-15 |
Hong Guan
CHM | Chairman | 47 | 01-04-10 |
Wei Guo Zhang
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-04-14 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 96 000 000 | 30 192 000 ( 31,45 %) | 0 | 31,45 % |
Bedrijfsgegevens
R&G PharmaStudies Co., Ltd.
North Tower, Huatong Building 19 Chegongzhuang West Road
100048, Beijing
+
http://www.rg-pharma.comSector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Winst van het jaar - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
-24,15% | 651 mln. | |
+16,17% | 82,36 mld. | |
-29,41% | 69,97 mld. | |
+10,99% | 29,41 mld. | |
-11,35% | 16,99 mld. | |
+1,43% | 17,08 mld. | |
-0,68% | 15,21 mld. | |
+1,50% | 11,84 mld. | |
+3,44% | 13,25 mld. | |
+31,43% | 12,08 mld. |
- Beurs
- Aandelen
- Koers 301333
- Onderneming R&G PharmaStudies Co., Ltd.